Menu
Search
|

Menu

Close
X

Chembio Diagnostics Inc CEMI.OQ (NASDAQ Stock Exchange Capital Market)

6.09 USD
-- (--)
As of Jul 22
Previous Close 6.09
Open --
Volume --
3m Avg Volume 15,216
Today’s High --
Today’s Low --
52 Week High 11.55
52 Week Low 4.87
Shares Outstanding (mil) 12.31
Market Capitalization (mil) 77.55
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY19
8
FY18
33
FY17
24
FY16
18
EPS (USD)
FY19
-0.164
FY18
-0.531
FY17
-0.518
FY16
-1.299
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.67
Price to Sales (TTM)
vs sector
4.21
7.92
Price to Book (MRQ)
vs sector
5.03
5.39
Price to Cash Flow (TTM)
vs sector
--
24.37
Total Debt to Equity (MRQ)
vs sector
0.00
14.56
LT Debt to Equity (MRQ)
vs sector
0.00
10.21
Return on Investment (TTM)
vs sector
-68.16
14.49
Return on Equity (TTM)
vs sector
-69.09
15.79

EXECUTIVE LEADERSHIP

Katherine Davis
Non-Executive Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
John Sperzel
President, Chief Executive Officer, Director, Since 2017
Salary: $298,558.00
Bonus: --
Neil Goldman
Chief Financial Officer, Executive Vice President, Since 2017
Salary: --
Bonus: --
Javan Esfandiari
Chief Science and Technology Officer, Since 2015
Salary: $315,000.00
Bonus: $90,000.00
Tom Ippolito
Vice President - Regulatory Affairs, Quality Assurance and Quality Control, Since 2005
Salary: $196,187.00
Bonus: $33,600.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

555 Wireless Blvd
HAUPPAUGE   NY   11788-3966

Phone: +1631.9241135
Site: chembio.com/

Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company's products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company's product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.

SPONSORED STORIES